• First Sofdra™ prescriptions issued in December as part of Patient Experience Program, with 100% refill follow up in January
• Full commercial launch of Sofdra with field sales force now underway, to be followed by expanded digital program
• All sales professionals trained and certified, ready to drive Sofdra adoption in dermatology offices

Botanix Pharmaceuticals Ltd has released its Quarterly Activity Report and Appendix 4C Quarterly Cash Flow report for the period ended 31 December 2024. The key highlights include the first prescriptions for Sofdra™ (sofpironium) topical gel, 12.45% being issued as part of the Patient Experience Program, with 100% refill follow up in January, proving up the telehealth and closed fulfilment systems. The full commercial launch of Sofdra is now underway, with the field sales force deployed and all sales professionals trained and certified. Botanix has also finalized contractual terms with all key US commercial payers, reflecting the target financial and patient access restrictions. The company has completed all requirements for US government payer programs, with Sofdra to be available for an additional ~80 million lives from March 2025. Q1 CY2025 will represent the first commercial revenue quarter for Sofdra, with Q2 CY2025 expected to see a significant ramp in revenue following the full deployment of direct and digital sales channels. Botanix ended the quarter with a cash position of A$48.36 million and no debt.

Botanix expects Q1 CY2025 to represent the first commercial revenue quarter for Sofdra, with Q2 CY2025 expected to reflect a significant ramp in revenue following the full deployment of both direct and digital sales channels.